G-protein-coupled receptors (GPCRs) pose challenges for drug discovery efforts because of the high degree of structural homology in the orthosteric pocket, particularly for GPCRs within a single subfamily, such as the nine adrenergic receptors. Allosteric ligands may bind to less-conserved regions of these receptors and therefore are more likely to be selective. Unlike orthosteric ligands, which tonically activate or inhibit signalling, allosteric ligands modulate physiologic responses to hormones and neurotransmitters, and may therefore have fewer adverse effects. The majority of GPCR crystal structures published to date were obtained with receptors bound to orthosteric antagonists, and only a few structures bound to allosteric ligands have been reported. Compound 15 (Cmpd-15) is an allosteric modulator of the β 2 adrenergic receptor (β 2 AR) that was recently isolated from a DNA-encoded small-molecule library 1 . Orthosteric β-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in the world and Cmpd-15 is the first allosteric beta-blocker. Cmpd-15 exhibits negative cooperativity with agonists and positive cooperativity with inverse agonists. Here we present the structure of the β 2 AR bound to a polyethylene glycol-carboxylic acid derivative (Cmpd-15PA) of this modulator. Cmpd-15PA binds to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8. A comparison of this structure with inactive-and active-state structures of the β 2 AR reveals the mechanism by which Cmpd-15 modulates agonist binding affinity and signalling.
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. Orthosteric β-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in the world and Cmpd-15 is the first allosteric beta-blocker. Cmpd-15 exhibits negative cooperativity with agonists and positive cooperativity with inverse agonists. Here we present the structure of the β 2 AR bound to a polyethylene glycol-carboxylic acid derivative (Cmpd-15PA) of this modulator. Cmpd-15PA binds to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8. A comparison of this structure with inactive-and active-state structures of the β 2 AR reveals the mechanism by which Cmpd-15 modulates agonist binding affinity and signalling.
There is growing interest in the identification of allosteric ligands for GPCRs owing to their ability to modulate the activity of native hormones and neurotransmitters, and the greater potential for subtype selectivity. We previously reported the structure of the activestate M2 muscarinic receptor with a positive allosteric modulator bound within the extracellular vestibule where it stabilized the active state and slowed agonist dissociation 2 . Previously, several groups have reported modulators binding within the intracellular surface of GPCRs 3, 4 and to the outer surface of transmembrane segments 5 . Cmpd-15, 4-((2S)-3-(((S)-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide, is a membrane-permeable negative allosteric modulator of β 2 AR that was isolated from a DNA-encoded small-molecule library 1 . Of interest, unlike conventional drug discovery methods, this screen using purified β 2 AR protein unoccupied by any ligand was unbiased, allowing us to identify molecules capable of binding to any surface of the receptor, not just the orthosteric pocket. Biochemical and pharmacological characterization showed that Cmpd-15 crosses the plasma membrane and binds to the intracellular surface of the β 2 AR. In an effort to understand the mechanism by which Cmpd-15 stabilizes the inactive state and inhibits coupling to G proteins and β-arrestins, we obtained a crystal structure of the β 2 AR bound to Cmpd-15.
We used a previously described β 2 AR-T4 lysozyme fusion protein (β 2 AR-T4L) 6 to obtain a crystal structure of the inactive state of the β 2 AR bound to the orthosteric antagonist carazolol and Cmpd-15. In initial trials, purified β 2 AR-T4L was crystallized in lipid cubic phase in the presence of 200 μM Cmpd-15 (limit of solubility), and a structure was determined by molecular replacement at 2.5 Å. The structure revealed weak positive electron density near the cytoplasmic ends of transmembrane (TM) segments 1, 2, 6 and 7, but it was not possible to unambiguously dock Cmpd-15 into the density. To improve the occupancy of Cmpd-15 in crystallized β 2 AR, a molecule of carboxylic acid functionalized polyethylene glycol was added to the position used for coupling of the molecule to its DNA tag (Fig. 1a) . The modified Cmpd-15, Cmpd-15 polyethylene glycol-carboxylic acid derivative (denoted as Cmpd-15PA) exhibits comparable effects on orthosteric agonist binding affinity to the parent Cmpd-15 (Fig. 1b, Extended Data  Fig. 1a) . Furthermore, binding of Cmpd-15PA leads to a comparable decrease in orthosteric agonist binding affinity for both the β 2 AR-T4L and wild-type β 2 AR (Extended Data Fig. 1b) . As expected, Cmpd-15PA was more soluble than Cmpd-15 and we were able to crystallize β 2 AR-T4L bound to the orthosteric antagonist carazolol in the presence of 1 mM Cmpd-15PA. The structure was solved by molecular replacement at 2.7 Å (Methods, Extended Data Table 1 ). We observed a well-defined F o − F c simulated annealing omit map for Cmpd-15PA (Fig. 1c, green map) . The relatively weak electron density for the bromine substituent is most likely due to its susceptibility to radiation damage. This was confirmed by a 'radiation damage map' . The diffraction data from each crystal was divided into two sets: data collected early, having the least radiation damage, and the remaining data, having the greatest radiation damage. These early and late data were separately merged, and an isomorphous F o early − F o late difference electron density map revealed a strong peak around the bromine atom (Fig. 1c , purple map, Extended Data Fig. 2 ).
As suggested from previous studies 1 , Cmpd-15PA binds to the intracellular surface of the β 2 AR. It lies partially buried in a pocket formed by TMs 1, 2, 6, 7, helix 8 (H8) and intracellular loop 1 (ICL1) (Fig. 1d-f ). There is no clear electron density for the polyethylene glycol-carboxylic acid moiety of Cmpd-15PA, suggesting that it is disordered in the crystal structure. Cmpd-15PA forms polar interactions with side chains of Thr274 Fig. 3 ). It should be noted that Cmpd-15PA is a racemic mixture with respect to the chiral carbon connecting the cyclohexyl and phenyl rings (Fig. 1a) . We docked both isomers and found that the R isomer fits better into the electron density (Extended Data Fig. 4) ; therefore, we used the R isomer for all figures and for the analysis of interactions between Cmpd-15PA and the β 2 AR.
Cmpd-15PA stabilizes TM6 in the inactive state through direct polar interactions with side chain of Thr274 6.36 and non-polar interactions with side chains of Ala271 6.33 and Leu275 6.37 ( Fig. 3a) . It also indirectly stabilizes interactions between TM6 and H8 through the formation of a new salt bridge. Figure 3 illustrates differences in the crystal structure of β 2 AR-T4L bound only to carazolol (Fig. 3b) and β 2 AR-T4L bound to both carazolol and Cmpd-15PA (Fig. 3a) . The bromophenyl ring of Cmpd-15PA disrupts a salt bridge between Arg63 ICL1 in ICL1 and Asp331 8.49 in H8 enabling the formation of a new salt bridge between Lys267 6.29 at the end of TM6 and Asp331 8.49 in H8. This salt bridge also serves to trap Cmpd-15PA in its binding pocket. In molecular dynamics simulations, this salt bridge exhibited consistent stability in the presence of Cmpd-15. It was present in 86.4 ± 5.1% of simulation frames (mean and standard deviation reported for five independent simulations). Molecular dynamics simulations also suggest that TM6 is stabilized in a more inward conformation when bound to Cmpd-15 (Fig. 3c) . The binding of Cmpd-15PA also necessitates concerted rearrangement of the side chains of Phe332 8.50 and Phe336 8.54 , which changes the shape of the binding pocket (Fig. 3a, b and Extended Data Fig. 5 ). In addition to stabilizing the inactive conformation of TM6, would sterically clash with Cmpd-15 ( Fig. 3d) . On the basis of the β 2 AR-G s crystal structure 7 , Cmpd-15 would also be expected to sterically interfere with G s coupling (Fig. 3e ). This will probably be true for β 2 AR-β-arrestin interactions on the basis of the structure of the rhodopsin-arrestin complex 8 . When bound to Cmpd-15, the β 2 AR exhibits negative cooperativity for isoproterenol (Fig. 1b) and positive cooperativity for the inverse agonist ICI-118,551 (ref. 1). We previously reported the structure of the β 2 AR bound to an allosteric nanobody (Nb60) that stabilized the inactive state 9 . The Nb60 binding pocket partially overlaps with the Cmpd-15PA pocket (Extended Data Fig. 6a ), but Nb60 also interacts with TM3 and ICL2. With the exception of side-chains in direct contact with Nb60 or Cmpd-15, the two structures are nearly identical (Extended Data Fig. 6b-d Figure 6d shows a comparison of the orthosteric binding pocket of β 2 AR bound to the inverse agonist carazolol alone (Protein Data Bank, accession number 2RH1), or together with Cmpd-15. Although we observed subtle differences in the position of Y308 7. 35 , this is more likely due to differences in the crystal lattice packing interactions involving extracellular loop 3, and not to allosteric effects of Cmpd-15. The effect of Cmpd-15 and Nb60 on agonist and inverse-agonist binding affinity is probably due to their ability to stabilize TM6 in an inactive conformation. Equilibrium binding affinity represents the average affinity of multiple conformations of the receptor that exchange on time scales that are much faster than the time required for the equilibrium binding study. Therefore, in this experimental setting, as both Cmpd-15 and Nb60 stabilize the inactive state, this results in a lower affinity for agonists and a higher affinity for inverse agonists. Nb60 has a greater effect on agonist binding affinity than 
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Cmpd-15 (70-fold increase in K i with Nb60 and tenfold increase with Cmpd-15). The greater effect of Nb60 is probably due at least in part to the higher affinity of its interaction with the β 2 AR (56.8 nM for Nb60 (ref. 9) and 1.7 μM for Cmpd-15 (ref. 1)).
To validate the binding pocket of Cmpd-15, we examined the effect of mutations of amino acid side chains that interact with different regions of the ligand. As can be seen in Fig. 4 , mutation of Thr274 6.36 to Ala disrupts polar interactions with the formamide functionality of the methylbenzamide group and mutation of Asn69 2. 40 to Ala disrupts polar interactions with a backbone carbonyl. Mutation of Ile72 2.43 to Ala results in the loss of non-polar van der Waals interactions with the cyclohexylmethyl-benzene group. All three mutations result in a diminution of inhibitory activity of Cmpd-15, both the maximal effect on arrestin recruitment and the shift in half maximal effective concentration (EC 50 ) for isoproterenol ( Fig. 4b-e) . It is interesting to note that mutations of amino acids that form the Cmpd-15 binding pocket have a greater effect on the fold change in EC 50 for isoproterenol than on the maximal inhibition of arrestin recruitment. These results suggest that the ability of Cmpd-15 to sterically disrupt interactions between the β 2 AR and β-arrestin can be separated from the effects of Cmpd-15 on stabilization of TM6 in an inactive conformation with associated allosteric effects on agonist affinity.
The functional effects of different chemical modifications to Cmpd-15 are shown in Extended Data Fig. 7 . The crystal structure helps to explain the observed activity of different analogues on orthosteric agonist binding affinity, and cell-based assays for cAMP production and β-arrestin recruitment. The greatest loss of activity was observed for compounds A1, A6 and A7.
Compound A1 lacks the formamide functionality on the methylbenzamide group that forms a hydrogen bond with Thr274 6.36 in TM6 (Fig. 4a ), whereas either hydroxyl or methoxy substitution at the para-position on the phenyl ring of cyclohexylmethylbenzene group (compounds A6 and A7) would sterically clash with TM6 (Fig. 2b) . Loss of the bromine at the meta-position of the bromo-benzyl group (compound A4) also had significant effects in cell-based signalling assays, which may be due to loss of van der Waals interactions of the Br with the side chains of Phe61 1.60 and Leu64
ICL1
in ICL1 (Fig. 4a) . Allosteric ligands may exhibit greater subtype selectivity than orthosteric compounds. Cmpd-15 is more efficacious at inhibiting β 2 AR activities than β 1 AR 1 , although all of the 21 amino acids that form the Cmpd-15 binding pocket are conserved except for Phe61 at the cytoplasmic end of TM1 and Lys267 6.29 in TM6, which are Thr and Arg in the homologous position of the β 1 AR (Extended Data Fig. 8a, b ). As noted above, Phe61 may have aromatic interactions with the bromo-benzyl group. Notably, unlike its pronounced effect on agonist binding to β 2 AR, Cmpd-15 has no effect on orthosteric agonist binding affinity to the β 1 AR (Extended Data Fig. 8c ). This result, together with the previously reported cellular activity data 1 and mutagenesis data discussed above, further supports the dual mechanisms by which Cmpd-15 exerts its negative effects on receptor activity. Cmpd-15 specifically reduces the binding affinity of the β 2 AR orthosteric agonists by stabilizing its inactive conformation (allosteric effect), but it may sterically interfere with transducer coupling to a broader range of receptors such as the β 1 AR (Fig. 3e ). Cmpd-15 was found to have much weaker activity at the G s -coupled vasopressin receptor type 2, where only 7 of the 21 binding-pocket residues are identical, and almost no activity at the G q -coupled angiotensin type 1 receptor where only 6 of the 21 residues are identical 1 (Extended Data Fig. 8a, b) .
Recently, crystal structures of two chemokine receptors with negative allosteric modulators bound to the intracellular surface were reported. CC chemokine receptor 2 (CCR2) was crystallized with T4 lysozyme inserted between TMs 5 and 6 and bound to the orthosteric antagonist BMS-681 and an allosteric antagonist (CCR2-RA-(R)) 3 . CCR2-RA-(R) binds cooperatively with BMS-681, and the two ligands have an additive effect on the thermostability of CCR2. As shown in Extended Data Fig. 9a , b, the binding pocket for CCR2-RA-(R) is similar to that for Cmpd-15PA involving the cytoplasmic ends of TMs 1, 2, 6 and 7, but the ligand also makes contact with R 3.50 in TM3. CCR9 with eight thermostabilizing mutations was crystallized bound to the antagonist vercirnon 4 . Vercirnon was thought to be an orthosteric antagonist, and it was therefore surprising that they found that it bound to an intracellular pocket with no ligand occupying the orthosteric pocket. No information was provided regarding the effect of vercirnon on the binding of orthosteric ligands. Like CCR2-RA-(R), vercirnon engages more TM segments than Cmpd-15PA and binds to a pocket formed by the intracellular ends of TMs 1, 2, 3, 6 and 7 (Extended Data Fig. 9c ). It is interesting to note that the location of this binding site is very similar for all three receptors (a pocket formed by the cytoplasmic ends of TMs 1, 2, 6, 7), yet the structure of the allosteric ligands and the chemical interactions between the receptors and ligands are different. These observations suggest that this site may represent a druggable target for other GPCRs.
The structure of the β 2 AR bound to Cmpd-15PA in comparison with inactive-and active-state structures of the β 2 AR provides detailed mechanistic insights into its ability to modulate both orthosteric ligand binding and signalling. Like Nb60, Cmpd-15 sterically prevents coup ling to G s , and probably blocks interactions with GPCR kinases and arrestins as well. The effect of Cmpd-15 on agonist binding affinity is probably the result of stabilizing the inactive conformation of TM6. We previously showed that the G protein G s and positive allosteric nanobodies for the β 2 AR Letter reSeArCH the μ-opioid receptor 12 all stabilize the outward displacement of the cytoplasmic end of TM6, and also stabilize a high-affinity state for agonists. Cmpd-15, like Nb60, stabilizes the inactive conformation of TM6 associated with reduced affinity for agonists 1 . These results, together with the recent structures of CCR2 and CCR9 bound to intracellular modulators, suggest that the location of this intracellular allosteric pocket may be widely conserved amongst diverse GPCRs and that there may be potential therapeutic value in targeting this surface for drug discovery.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper. . Protein expression and purification was performed as previously described 13 with minor modifications. In brief, the receptor was expressed in Sf9 cells (obtained from Expressions Systems, LLC). Cell membranes were solubilized with solubilization buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 1% DDM). 30 μM atenolol (Sigma) was added during solubilization to stabilize the receptor. Solubilized receptors were isolate on M1-Flag affinity resin (Sigma). Atenolol was then washed away and target protein was eluted by HMS-CHS buffer (20 mM HEPES, pH 7.5, 350 mM NaCl, 0.1% DDM, 0.02% CHS) plus 0.2 mg ml −1 Flag peptide and 5 mM EDTA. The M1-Flag-purified β 2 AR-T4L was treated with TCEP/iodoacetamide and applied to alprenolol-Sepharose affinity resin 13 to isolate functional protein. The eluted alprenolol bound receptor was then loaded onto a second M1-Flag column, on which the detergent was changed from 0.1% DDM to 0.01% MNG and ligand was changed from alprenolol to 20 μM carazolol (Sigma) and 50 μM Cmpd-15PA. The eluted β 2 AR-T4L was dialysed against dialysis buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 0.003% MNG, 0.0003% CHS, 10 μM carazolol, 10 μM Cmpd-15PA) overnight at 4 °C to remove excess EDTA and Flag peptide. PNGase F (New England Biolabs) was added to the protein during dialysis to remove N-linked sugars and purified β 2 AR-T4L was concentrated to ~50 mg ml −1 with a 50 kDa cutoff Amicon centrifugal filters (Millipore). Crystallization. Concentrated protein was mixed with monoolein (Sigma) containing 10% (w/w) cholesterol (Sigma) to form lipidic cubic phase (LCP) using the previously reported two-syringe method 14 . The protein solution to lipid ratio was 2:3 (w/w). Once clear LCP was formed, crystal trials were set up by filling 96-well glass sandwich plates with 30 nl of LCP overlaid with 1 μl precipitant solution using an LCP crystallization robot (Gryphon, Art Robbins Instruments). The best diffracting crystals were grown in 0.1 M Tris-HCl, pH 7.5, 30-37.5% PEG400, 400 mM NH 4 F, 6% 1,4-butanediol, 1 mM Cmpd-15PA and 1% DMSO. Crystals appeared after 1 day and grew to full size within 1 week. Data collection and structure determination. Crystals were collected in 50 μm MicroMeso loops (MiTeGen) and flash-frozen in liquid nitrogen. Diffraction data were collected at beamline BL32XU at SPring-8, Japan. Typically, 10 to 20 degrees of data were collected for each crystal. Diffraction data were processed with XDS 15 . Analysis with UCLA Diffraction Anisotropy Server 16 suggested that the diffraction data were anisotropic. An anisotropy-truncated dataset was generated with resolution limits set to 3.1 Å, 2.7 Å and 2.8 Å along the a*, b* and c* axis, respectively, and we report this structure at a maximum resolution of 2.7 Å. The CC 1/2 of 0.746 indicates that the high-resolution shell contains useful information, even though the completeness is low owing to anisotropic truncation (Extended Data Table 1 ). The structure was solved by molecular replacement using phenix.automr 17 , with the previously reported β 2 AR-T4L structure (PDB, 2RH1) as a search model. The allosteric ligand and residues that undergo large conformational changes were manually fit into F o − F c electron density maps in Coot 18 . Structure refinement was performed with phenix.refine 17 , with individual B factors refined for protein and ligands. The occupancy of Cmpd-15PA was refined as a single group, with a final value of 82%. The final model was validated using Molprobity 19 . Data collection statistics and structure refinement statistics are summarized in Extended Data Table 1. All structure figures were prepared using PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC.).
Author Contributions
The position of the ligand was found by isomorphous difference Fourier analysis. Diffraction data from crystals without Cmpd-15PA were scaled to the Cmpd-15PA data, and an F o − F o map between these two datasets was computed using FFT 20 in CCP4 21 . A similar strategy was used to calculate the radiation damage map: diffraction data from the first 5 degrees and the second 5 degrees of each crystal were merged into two different datasets. After scaling these two datasets together, an F o − F o difference map was calculated by subtracting the second half of data from the first half of data. The model was confirmed using an F o − F c simulated annealing omit map calculated with Phenix 17 , using a starting temperature of 3,000 K and a starting model in which Cmpd-15PA was omitted. Contact surface between ligand and receptor was calculated with PISA 22 in CCP4
21
. Radio-ligand binding. Assays were performed as previously described 1 . Competition binding was performed with approximately 0.7 ng of βARs in HDL particles diluted in an assay buffer (20 mM HEPES, pH7.4, 100 mM NaCl, 0.1% BSA and 1 mM ascorbic acid). Receptors reconstituted in HDL particles were prepared as previously described 23 . βARs in HDL particles were mixed with Cmpd-15PA or Cmpd-15 at different concentrations and a quarter or half log serial dilution of isoproterenol with the constant concentration of 125 I-cyanopindolol (CYP) (2,200 Ci mmol −1 ; PerkinElmer) at 60 pM. Propranolol at 20 μM was used to determine non-specific binding. Following 90-min incubation at room temperature, binding assays were terminated by rapid filtration onto GF/B glassfibre filters (Brandel) treated with 0.3% polyethyleneimine (PEI). The filters were then washed with 8 ml of a cold binding buffer (20 mM HEPES, pH7.4, 100 mM NaCl) using a harvester (Brandel). Bound [ 125 I] was quantified using a Packard Cobra Quantum gamma counter (Packard) and expressed as specific binding.
3 H-methoxyfenoterol ( 3 H-Fen) binding was carried out with isolated membranes from Sf9 cells exogenously expressing the phosphorylated forms of the β 2 V 2 R. Membranes with phosphorylated forms of the receptor were prepared essentially following the procedures described previously 24 . Approximately 40 μg of the isolated membranes in binding buffer (50 mM Tris, pH 7.4, 2 mM EDTA, 12.5 mM MgCl 2 , 0.05% BSA and 1 mM ascorbic acid) were mixed either with a serial dilution of Cmpd-15 or Cmpd-15PA, or with a single dose of Cmpd-15 analogues at 32 μM. Then 4.3 nM 3 H-Fen and transducers (100 nM heterotrimeric G s or 250 nM β-arrestin1 together with 0.5 μM Fab30) were added to the mixture. Following incubation for 90 min at room temperature, binding assays were terminated by collecting the reaction mixture on to PEI-soaked GF/B filters. Bound 3 H was extracted over night with 5 ml scintillation fluid and quantified using a Tri-Carb 2800TR liquid scintillation counter (PerkinElmer). Measurements of β-arrestin recruitment. The extent of β-arrestin recruitment to the β 2 AR was monitored using PathHunter, a chemiluminescence-based enzyme fragment complementation assay (DiscoveRx) as previously described 1 . For the mutagenesis study, U2OS cells stably expressing enzyme acceptor-tagged β-arrestin2 (DiscoveRx) were transiently transfected with ProLink-tagged β 2 AR mutant constructs using FuGENE 6 (Promega). These mutants were created on the wild-type ProLink-tagged β 2 AR provided by DiscoveRx using a quick-change sitedirected mutagenesis kit (Agilent). On the following day after transfection, cells were plated in 96-well white, clear-bottomed plates at a density of 25,000 cells per well. On another following day, cells were pre-treated with 0.5% dimethylsulfoxide (DMSO) or Cmpd-15 at different concentrations in Hank's balanced solution (Sigma), supplemented with 20 mM HEPES, pH 7.4 and 0.05% BSA and further incubated for 20 min. Subsequently, cells were stimulated with a serial dilution of isoproterenol for 1 h at 37 °C, which was terminated by adding PathHunter detection reagents (DiscoveRx). After further incubation for 1 h at 27 °C, luminescence signals were read using a NOVOstar microplate reader (BMG Labtech). For the study with Cmpd-15 analogues, U2OS cells stably expressing enzyme acceptortagged β-arrestin 2 and ProLink-tagged β 2 V 2 R were used. Measurements of cAMP production. The level of cAMP was monitored using Glosensor, a chemiluminescence-based cAMP biosensor (Promega) as previously described 1 . HEK-293 cells (ATCC) stably expressing Glosensor were plated in 96-well white, clear-bottomed plates at a density of 80,000 cells per well. On the following day, Glosensor reagents (Promega) were added, and cells were incubated in a 27 °C humidifying incubator for ~1 h. Cells were then further incubated with either the vehicle (DMSO) control or each of the Cmpd-15 analogues at 50 μM in Hank's balanced solution (Sigma), supplemented with 20 mM HEPES, pH 7.4 and 0.05% BSA, together with 100 μM 3-isobutyl-1-methylxanthine (IBMX, Sigma) for 20 min. At the end of incubation, cells were stimulated with a serial dilution of isoproterenol for 5 min at room temperature. Changes in luminescence were read using a NOVOstar microplate reader (BMG Labtech). Molecular dynamics simulations setup. Molecular dynamics simulations of β 2 AR were initiated from the carazolol-and Cmpd-15PA-bound crystal structure described in this manuscript. The receptor was simulated in two distinct conditions: (1) β 2 AR bound to carazolol and Cmpd-15 and (2) β 2 AR bound to carazolol only.
The structures were prepared by first removing the crystallized T4 lysozyme fragment and non-receptor molecules except for the ligands, water, and cholesterol. Prime (Schrödinger, Inc.) was used to model in missing side-chains. Hydrogen atoms were added, and protein chain termini were capped with the neutral groups acetyl and methylamide. In the simulations, titratable residues were left in their dominant protonation state at pH 7.0. Previous studies have suggested that residues D79
2.50 and D130 3.49 of β 2 AR may be deprotonated in the inactive state and protonated in the active state 25, 26 . As the crystal structures represent the inactive state, D79
2.50 and D130 3.49 were deprotonated in our simulations. Histidines were represented with hydrogen on the epsilon nitrogen.
The carazolol tertiary amine nitrogen was protonated, corresponding to the dominant protonation state at pH 7.0 and enabling formation of the conserved salt bridge with neighbouring D113 3.32 . The prepared protein structures were aligned on the transmembrane helices to the orientation of proteins in membranes (OPM) 27 structure of PDB 2RH1. The structures were then inserted Letter reSeArCH into a pre-equilibrated palmitoyl-oleoyl-phosphatidylcholine (POPC) bilayer. Final system dimensions were approximately 75 × 75 × 95 Å 3 , including approximately 141 lipids, 10,840 water molecules, 23 sodium ions, 29 chloride ions, and 2 cholesterol molecules. Molecular dynamics simulation force field parameters. We used the CHARMM36 parameter set for protein molecules, lipid molecules, and salt ions, and the CHARMM TIP3P model for water; protein parameters incorporated CMAP terms [28] [29] [30] [31] [32] . Parameters for carazolol and Cmpd-15 were generated using the CHARMM General Force Field (CGenFF) [33] [34] [35] with the ParamChem server (https://www.paramchem.org/), version 1.0.0. Full parameter sets are available upon request. Molecular dynamics simulation protocol. Simulations were performed on GPUs using the CUDA version of PMEMD (Particle Mesh Ewald Molecular Dynamics) in Amber16 36, 37 . Prepared systems were minimized, then equilibrated as follows: the system was heated using the Langevin thermostat from 0 to 100 K in the NVT ensemble over 12.5 ps with harmonic restraints of 10.0 kcal mol −1 Å −2 on the non-hydrogen atoms of lipid, protein, and ligand, and initial velocities sampled from the Boltzman distribution. The system was then heated to 310 K over 125 ps in the NPT ensemble with semi-isotropic pressure coupling and a pressure of one bar. Further equilibration was performed at 310 K with harmonic restraints on the protein and ligand starting at 5.0 kcal mol −1 Å −2 and reduced by 1.0 kcal mol
stepwise every 2 ns for 10 ns and then by 0.1 kcal mol −1 Å −2 stepwise every 2 ns for 20 ns, for a total of 30 ns of additional restrained equilibration. Equilibration was followed by production simulations lasting between 4.0 and 5.0 μs each.
Five independent simulations were performed in the presence of Cmpd-15, for a total of 23.1 μs. Three independent simulations were performed in the absence of Cmpd-15, for a total of 15.1 μs. These simulations were conducted in the NPT ensemble at 310 K and 1 bar, using a Langevin thermostat and Monte Carlo barostat.
Simulations used periodic boundary conditions, and a time step of 4.0 fs, with hydrogen mass repartitioning 38 . Bond lengths to hydrogen atoms were constrained using SHAKE. Non-bonded interactions were cut off at 9.0 Å, and long-range electrostatic interactions were computed using the particle mesh Ewald (PME) method with an Ewald coefficient β of approximately 0.31 Å and B-spline interpolation of order 4. The FFT grid size was chosen such that the width of a grid cell was approximately 1 Å. Analysis protocols for molecular dynamics simulations. Trajectory snapshots were saved every 200 ps during production simulations. Trajectory analysis and visualization were performed using VMD TM6  TM7  TM1   H8   Cmpd-15  Nb60  TM6  TM5   TM7   H8   H8   TM6  TM5  TM7   TM2  TM3  TM1  TM4 TM7   TM2   TM1   H8   TM3   TM6   TM7   TM2   TM1   H8   TM3   TM6   TM7   TM2   TM1   H8   TM3 
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